Boston Scientific could gain a much-needed cash injection by selling its neuromodulation and neurovascular intervention businesses. Reports in the US press that the company could earn $2.2-2.4bn from divesting the two units began circulating last week. The combined revenue from both businesses ...
Please Login to read the full article.
